CD8 (cluster of differentiation 8)

Furthermore, we explore the therapeutic potential of targeting ferroptosis using both natural compounds and synthetic agents, which have shown promise in inducing ferroptosis and suppressing tumor growth in preclinical models. Notably, emerging evidence suggests that activating ferroptosis may help overcome radioiodine resistance and improve survival outcomes, particularly in aggressive subtypes such as anaplastic thyroid cancer (ATC). Therefore, the exploitation of ferroptosis offers a promising avenue to address therapeutic resistance and improve prognosis in thyroid cancer, which merits further clinical investigation.

Regulatory oversight remains inconsistent, with limited phytochemical standardization. Ashwagandha shows multidimensional promise but requires rigorous, standardized clinical validation.

We remain optimistic about the critical role of ADAM10 in cytokine-induced T cell exhaustion, recruitment of immunosuppressive cells into the TME, and CD8+ T cell death/survival. Gaining significant insights into these processes may offer new strategies to advance CD8+ T cell-mediated cancer therapy.

In contrast, reactive/benign T-LGLs in the control group showed more variable expression of CD62L and CD45RA and more frequent functional subsets other than TEMRA cells. There is significant overlap between leukemic T-LGLs and reactive/benign T-LGLs in terms of common T-cell antigen expression and naïve/memory/effector T-cell subsets.

Post-transplant cyclophosphamide (PT-CY) remains the standard of care for graft-versus-host disease (GvHD) prophylaxis in haploidentical hematopoietic cell transplantation (HCT), yet relapse, delayed immune reconstitution, infections, and organ toxicity represent persistent and clinically meaningful limitations. PT-BEN appears to be a mechanistically distinct strategy with immunomodulatory properties that requires randomized validation before platform-level conclusions can be drawn. A multicenter randomized trial incorporating a reduced-dose PT-CY comparator arm will be essential to establish PT-BEN's independent contribution and define its role in improving long-term HCT outcomes.

Second, CD4+ Th-derived EVs carried IL-5 and other effector molecules that promoted JAK-STAT signaling, eosinophil recruitment to tumor sites, and eosinophil-mediated tumor cell killing through degranulation. Moreover, CD4+ Th-derived EVs remodeled the tumor microenvironment by enhancing CD8+ T cell and eosinophil infiltration and activation, suggesting their potential role in immune regulation and cancer therapy.

Serial lumbar punctures with triple intrathecal chemotherapy (dexamethasone 5 mg + methotrexate 10 mg + cytarabine 30 mg) were performed throughout the treatment course; no abnormalities were detected in cerebrospinal fluid (CSF) routine, biochemistry, or flow cytometry assays, and no evidence of central nervous system (CNS) leukemia involvement was observed at any time point. Our preliminary clinical observation demonstrates that this integrated regimen may mitigate antigen escape and immunosuppressive TME-mediated drug resistance, and effectively function as a bridging strategy to allo-HSCT in high-risk patient populations. The 7-year event-free survival (EFS) and sustained disease control observed in this case provide valuable clinical insights for the structural optimization of armored CAR-T constructs and the design of future prospective clinical trials for R/R B-ALL.

Together, these findings indicate that tumor cell glycolysis "primes" the TME for aberrant vascular architecture and T-cell exclusion, and that modulating the tumor vasculature can unravel these mechanisms restoring immune responsiveness. This suggests that tailoring anti-angiogenic and immunotherapy combinations to the tumor glycolytic state and associated vasculature profiles may restore immune surveillance and overcome therapy resistance.

Mechanistically, TCA facilitates tumor progression by both activating the S1PR2/PI3K/AKT signaling pathway within tumor cells and suppressing CD8 + T cell infiltration and cytotoxic function in the tumor microenvironment. In summary, this study, using a mouse model, establishes a link between oral antibiotic-induced dysbiosis and accelerated breast cancer progression and proposes that TCA and its associated pathways may serve as potential targets for future TNBC therapies.

The combined detection of the CD4+/CD8+ ratio and nCD64 index in BALF improves the diagnostic efficacy for differentiating lung cancer from pulmonary infection.

Toll-like receptor 7/8 agonists (TLR7/8a), such as resiquimod (R848), are highly potent in activating dendritic cells and thus hold promise for T cell-mediated tumor immunotherapies...Furthermore, the R848 functional concentration assay demonstrated that the micropump prolonged the treatment time of R848 drugs in tumors and reduced the requirement for higher doses, enhancing safety. Taken together, this study provides new insights into TLR7/8a immunotherapy for improved clinical performance, with potential benefits for patients with superficial tumors amenable to prolonged intratumoral infusion via micropump.

The six-gene diagnostic signature showed preliminary discriminatory ability in the available datasets, while the ceRNA regulatory network and natural compound screening results prioritize candidate regulatory pathways and compounds for future validation. These findings advance our understanding of AS pathogenesis and may guide future biomarker development and targeted intervention strategies.